To the best of our knowledge, this will be the first multicenter, prospective, observational study aimed to evaluate the safety and effectiveness of osimertinib with chemotherapy in Chinese patients with metastatic NSCLC harboring an EGFR exon 19 deletion and/or exon 21 L858R mutation in a real-world setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.